Literature DB >> 24048788

Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells.

Zhimin Tong1, Subhankar Chakraborty, Bokyung Sung, Pooja Koolwal, Sukhwinder Kaur, Bharat B Aggarwal, Sendurai A Mani, Robert S Bresalier, Surinder K Batra, Sushovan Guha.   

Abstract

BACKGROUND: The authors previously reported that neutrophil gelatinase-associated lipocalin (NGAL) overexpression significantly blocked invasion and angiogenesis of pancreatic ductal adenocarcinoma (PDAC). They also demonstrated a loss of NGAL expression in the advanced stages of PDAC. However, little is known regarding the mechanisms of NGAL regulation in PDAC. Because the epidermal growth factor (EGF)-EGF receptor (EGFR) axis is up-regulated significantly in PDAC, they examined EGF-mediated NGAL regulation in these cells.
METHODS: The NGAL-positive cell lines AsPC-1 and BxPC-3 were used as a model system. Quantitative real-time polymerase chain reaction (RT-PCR), Western blot analysis, and immunofluorescence studies were used to investigate EGF-mediated effects on NGAL expression. E-cadherin expression was manipulated using lentiviral overexpression or small hairpin RNA constructs. NGAL promoter activity was assessed by luciferase-reporter assay and electrophoretic mobility shift assay.
RESULTS: NGAL expression was positively associated with tumor differentiation and was down-regulated significantly after EGF treatment along with a concomitant reduction of E-cadherin expression in PDAC cells. E-cadherin down-regulation was partly through the EGFR-dependent mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) (MEK-ERK) signaling pathway. In addition, E-cadherin down-regulation reduced NGAL expression in PDAC cells, whereas overexpression of E-cadherin led to increased NGAL expression and partly rescued the inhibition of NGAL expression by EGF. Furthermore, EGF, in part through E-cadherin, reduced NGAL promoter activity by blocking nuclear factor κB (NF-κB) activation.
CONCLUSIONS: The current study demonstrated for the first time that EGF potently blocked NGAL expression in PDAC cells. This effect was mediated in part through activation of the EGFR-MEK-ERK signaling pathway, which, in turn, down-regulated E-cadherin with a subsequent reduction in NF-κB activation. These findings illustrate a novel mechanism by which EGF regulates NGAL expression in PDAC.
Copyright © 2010 American Cancer Society.

Entities:  

Keywords:  E-cadherin; epidermal growth factor; neutrophil gelatinase associated lipocalin; nuclear factor κB; pancreatic cancer

Mesh:

Substances:

Year:  2010        PMID: 24048788      PMCID: PMC3134548          DOI: 10.1002/cncr.25803

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  48 in total

1.  Epidermal growth factor-dependent enhancement of invasiveness of squamous cell carcinoma of the breast.

Authors:  Fuyo Kimura; Keiichi Iwaya; Tokuichi Kawaguchi; Hiroshi Kaise; Kimito Yamada; Kiyoshi Mukai; Osamu Matsubara; Norihiko Ikeda; Norio Kohno
Journal:  Cancer Sci       Date:  2010-02-08       Impact factor: 6.716

2.  Expression of E-cadherin, alpha- and beta-catenins in patients with pancreatic adenocarcinoma.

Authors:  Young-Eun Joo; Jong-Sun Rew; Chang-Soo Park; Sei-Jong Kim
Journal:  Pancreatology       Date:  2002       Impact factor: 3.996

3.  Epidermal growth factor-induced GnRH-II synthesis contributes to ovarian cancer cell invasion.

Authors:  Song Ling Poon; Gareth T Hammond; Peter C K Leung
Journal:  Mol Endocrinol       Date:  2009-07-16

4.  PKC-beta1 isoform activation is required for EGF-induced NF-kappaB inactivation and IkappaBalpha stabilization and protection of F-actin assembly and barrier function in enterocyte monolayers.

Authors:  A Banan; L J Zhang; A Farhadi; J Z Fields; M Shaikh; A Keshavarzian
Journal:  Am J Physiol Cell Physiol       Date:  2003-11-05       Impact factor: 4.249

5.  Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma.

Authors:  Anna Pryczynicz; Katarzyna Guzińska-Ustymowicz; Andrzej Kemona; Jolanta Czyzewska
Journal:  Anticancer Res       Date:  2008 Mar-Apr       Impact factor: 2.480

6.  Cloning and expression of human neutrophil lipocalin cDNA derived from bone marrow and ovarian cancer cells.

Authors:  S Bartsch; H Tschesche
Journal:  FEBS Lett       Date:  1995-01-09       Impact factor: 4.124

7.  Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion.

Authors:  Zhimin Lu; Sourav Ghosh; Zhiyong Wang; Tony Hunter
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

8.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.

Authors:  Thiruvengadam Arumugam; Vijaya Ramachandran; Keith F Fournier; Huamin Wang; Lauren Marquis; James L Abbruzzese; Gary E Gallick; Craig D Logsdon; David J McConkey; Woonyoung Choi
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

Review 9.  Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene.

Authors:  Davide Bolignano; Valentina Donato; Antonio Lacquaniti; Maria Rosaria Fazio; Caterina Bono; Giuseppe Coppolino; Michele Buemi
Journal:  Cancer Lett       Date:  2009-06-18       Impact factor: 8.679

10.  Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia.

Authors:  N Moniaux; S Chakraborty; M Yalniz; J Gonzalez; V K Shostrom; J Standop; S M Lele; M Ouellette; P M Pour; A R Sasson; R E Brand; M A Hollingsworth; M Jain; S K Batra
Journal:  Br J Cancer       Date:  2008-04-08       Impact factor: 7.640

View more
  15 in total

1.  Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.

Authors:  Sobeyda B Gomez-Chou; Agnieszka Katarzyna Swidnicka-Siergiejko; Niharika Badi; Myrriah Chavez-Tomar; Gregory B Lesinski; Tanios Bekaii-Saab; Matthew R Farren; Thomas A Mace; Carl Schmidt; Yan Liu; Defeng Deng; Rosa F Hwang; Liran Zhou; Todd Moore; Deyali Chatterjee; Huamin Wang; Xiaohong Leng; Ralph B Arlinghaus; Craig D Logsdon; Zobeida Cruz-Monserrate
Journal:  Cancer Res       Date:  2017-03-01       Impact factor: 12.701

Review 2.  Lipocalin-2 expression and function in pancreatic diseases.

Authors:  Kristyn Gumpper; Andrew William Dangel; Valentina Pita-Grisanti; Somashekar G Krishna; Luis F Lara; Thomas Mace; Georgios I Papachristou; Darwin L Conwell; Phil A Hart; Zobeida Cruz-Monserrate
Journal:  Pancreatology       Date:  2020-01-07       Impact factor: 3.996

3.  Lipocalin-2-mediated upregulation of various antioxidants and growth factors protects bone marrow-derived mesenchymal stem cells against unfavorable microenvironments.

Authors:  Raheleh Halabian; Hossein Abdul Tehrani; Ali Jahanian-Najafabadi; Mehryar Habibi Roudkenar
Journal:  Cell Stress Chaperones       Date:  2013-04-26       Impact factor: 3.667

Review 4.  The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer.

Authors:  Subhankar Chakraborty; Sukhwinder Kaur; Sushovan Guha; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2012-03-31

5.  Lipocalin-2 is associated with a good prognosis and reversing epithelial-to-mesenchymal transition in pancreatic cancer.

Authors:  Bin Xu; Da-Yong Jin; Wen-Hui Lou; Dan-Song Wang
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

6.  Neutrophil gelatinase-associated lipocalin and its influence on tumor progression in systemic malignancies.

Authors:  Shailendra Kapoor
Journal:  World J Surg       Date:  2013-11       Impact factor: 3.352

Review 7.  Implication and role of neutrophil gelatinase-associated lipocalin in cancer: lipocalin-2 as a potential novel emerging comprehensive therapeutic target for a variety of cancer types.

Authors:  Sina Rahimi; Amaneh Mohammadi Roushandeh; Ebrahim Ahmadzadeh; Ali Jahanian-Najafabadi; Mehryar Habibi Roudkenar
Journal:  Mol Biol Rep       Date:  2020-01-22       Impact factor: 2.316

8.  MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-κB signaling in pancreatic cancer.

Authors:  Sukhwinder Kaur; Neil Sharma; Shiv Ram Krishn; Imay Lakshmanan; Satyanarayana Rachagani; Michael J Baine; Lynette M Smith; Subodh M Lele; Aaron R Sasson; Sushovan Guha; Kavita Mallya; Judy M Anderson; Michael A Hollingsworth; Surinder K Batra
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531

9.  Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer.

Authors:  Kostyantyn Krysan; Xiaoyan Cui; Brian K Gardner; Karen L Reckamp; Xiaoyan Wang; Longsheng Hong; Tonya C Walser; Nicole L Rodriguez; Paul C Pagano; Edward B Garon; John F Brothers; David Elashoff; Jay M Lee; Avrum E Spira; Sherven Sharma; Michael C Fishbein; Steven M Dubinett
Journal:  Am J Transl Res       Date:  2013-08-15       Impact factor: 4.060

10.  YueF overexpression inhibits cell proliferation partly through p21 upregulation in renal cell carcinoma.

Authors:  Hsuan-Wei Huang; Jian-Ping Peng; Jie Zhang
Journal:  Int J Mol Sci       Date:  2011-04-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.